Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

146,000 Orion Corporation A shares converted into B shares

Orion Oyj
Posted on: 01 Aug 17

ORION CORPORATION      STOCK EXCHANGE RELEASE 1 AUGUST 2017 at 9.00 a.m. EEST              

146,000 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 146,000 A shares have been converted into 146,000 B shares. The conversion has been entered into the Trade Register on 1 August 2017.

The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 37,120,346 A shares and 104,137,482 B shares. The number of votes of the company's shares is after the conversion 846 544 402.

   
Orion Corporation

Olli Huotari
SVP, Corporate Functions
  Jari Karlson
CFO
 

                                                                       
                                                                       
Contact person:
Mari Lautsuo, Communications Manager, tel. +358 10 426 2156

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Orion Oyj via GlobeNewswire
HUG#2124601
GlobeNewswire
globenewswire.com

Last updated on: 02/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.